News

Medigene announces market launch of Veregen® in Switzerland and market approval in 8 additional European countries

Martinsried/Munich, November 8, 2012. Medigene AG (MDG, Frankfurt, Prime Standard) announced today that Veregen® was launched in Switzerland by Medigene's partner Abbott. In addition, market approvals for the drug were granted in the Netherlands, Belgium, Finland, Slovenia, Hungary, Romania, Bulgaria, and Cyprus.

Veregen® is already being marketed in the USA (by Fougera), Germany and Austria (by Abbott), and Spain (by Bial) and approved in further countries. Marketing authorizations in additional countries are expected within the next few months. Medigene has entered into several marketing partnerships for Veregen® across Europe, Asia, and America, and is planning to continue this global licensing strategy in order to further exploit the market potential of Veregen®.

Veregen®: Veregen® (previously Polyphenon E® ointment) is a topical treatment for external genital warts, which contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. Medigene acquired the rights to the active ingredient in Veregen® from Epitome Pharmaceuticals, Inc. in 1999 and was solely responsible for the drug's successful preclinical and clinical development, as well as the approval process. Sinecatechins 15% ointment (Veregen®) is recommended as a possible option for treating genital warts in the US Department of Health and Human Services Center for Disease Control and Prevention's Sexually Transmitted Diseases Treatment Guidelines 2010.
 
Medigene AG is a publicly listed (Frankfurt: MDG, prime standard) biotechnology company headquartered near Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene was the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials, EndoTAG®-1 and RhuDex®; and is developing an innovative vaccine technology.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.

- End -

Kontakt Medigene AG
Public & Investor Relations
Julia Hofmann
Tel.: +49 - 89 - 20 00 33 - 33 01
Fax: +49 - 89 - 20 00 33 - 29 20
Email: investor@medigene.com

Pressemitteilungen abbestellen: www.medigene.de/unsubscribe